|
|||||
|
|
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib |
|
| Affiliation: | 1. Hematology and Stem Cell Transplantation, Yale University School of Medicine, New Haven, CT;2. Yale School of Medicine, Radiology and Biomedical Imaging, New Haven, CT;3. Departments of Laboratory Medicine and Medicine, Yale University School of Medicine, New Haven, CT;4. Department of Pharmacy, Yale New Haven Hospital, New Haven, CT;5. Infectious Diseases, Department of Medicine, Yale University School of Medicine, New Haven, CT |
| Abstract: | Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia. |
| Keywords: | Allogeneic stem cell transplantation COVID-19 Graft-versus-host disease Immunocompromised JAK inhibitor |
| 本文献已被 ScienceDirect 等数据库收录！ | |